Background {#Sec1}
==========

Cleft lip with or without cleft palate (CL/P) is a common congenital malformation affecting speech, hearing, feeding, among others functions \[[@CR1]\]. Individuals with CL/P require a comprehensive treatment, including multiple plastic and maxillofacial surgeries from birth to adulthood, and speech therapy \[[@CR2]\]. It has an average worldwide birth prevalence of 1 in 1000, ranging from 1 in 500 in the Asian population to 1 in 2500 in the African population, with wide variability per geographic origin, ethnicity, and socioeconomic status \[[@CR3], [@CR4]\]. The complexity of its etiology seems to result from various genetic and environmental risk factors along with gene- environment interactions (e.g., approximately 70% cases are non-syndromic) \[[@CR5]\]. Genome-wide association studies (GWAS) and linkage studies have identified genetic susceptibility to CL/P and differences in such susceptibility in various populations and ethnic groups \[[@CR6]\]. However, as seen in many complex diseases or traits, most of the mutations and loci identified from such studies are in the noncoding genomic regions and do not have specific functional annotations \[[@CR7], [@CR8]\]. Although much progress has been made in identifying genes whose mutations are associated with CL/P, little is known about the mechanisms by which environmental and epigenetic factors adversely influence gene expression during lip development. Recent studies indicate that environmental factors contribute to changes in phenotype or gene expression at post-transcriptional level through the regulation of noncoding RNAs, including microRNAs (miRNAs) \[[@CR9]\]. miRNAs are short (\~ 22 nucleotides) noncoding RNA molecules that regulate gene expression at the post- transcriptional level, and they fine-tune the expression of \~ 30% of all mammalian protein-encoding genes \[[@CR10]\]. miRNAs were first reported in mammalian systems in 2001 \[[@CR11]\], but the latest release of the miRNA database \[miRBase (ver. 20): more than 24,000 miRs annotated\] highlights the rapid growth of this field of research; however, the expression patterns and functions of most miRNAs still remain to be discovered. The miRNA-gene regulatory mechanisms contribute to the pathogenesis in various diseases \[[@CR12], [@CR13]\]. Nonetheless, a limited number of miRNAs (e.g. miRNA- 140, miRNA-17-92 cluster, miRNA-200b, miRNA-133b) have been reported as miRNAs involved in craniofacial deformities in zebrafish and mouse models, as well as in humans \[[@CR14]\]. Therefore, an investigation of the functional regulation, at the level of biological pathways and post- transcriptional regulation mechanism, will improve our understanding of genetic susceptibility to CL/P \[[@CR7], [@CR15]\].

In this study, in order to identify signatures of causative pathways in the complex etiology of CL/P, we performed a systematic review and subsequent bioinformatics analysis for CL/P-candidate genes. In addition, we analyzed miRNA-gene regulation by bioinformatics analyses. The function in cell proliferation/survival for six candidate miRNAs was experimentally evaluated by cell proliferation assays. Our findings will help us understand the role of genes and miRNAs that are associated with CL/P, in biological pathways and networks. Such knowledge will provide the basis for the diagnosis, prevention, and treatment of craniofacial anomalies such as CL/P.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

The publishing guidelines set forth by PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- Analyses) were followed during the literature search and review. The search was conducted using three main literature databases: Medline (Ovid), PubMed (NLM), and Embase (Ovid). In addition, related citations were searched in Scopus (Elsevier, Inc.) to check whether any unique studies were missed from the regular database searches.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The articles meeting the following eligibility criteria were included in our systematic review:described genes causing or potentially associated with CL/P in humans;referred to studies of either syndromic or non-syndromic CL/P;were published as original articles (not as review articles, editorials, dissertations, conference proceedings or comments);included cross-sectional, case-control, cohort studies, or clinical trials;were published in English.

After screening for articles using the criteria above, we manually excluded those articles in which:gene mutations were not described in the original articles;CL/P was not specifically described;CL/P resulted from environmental factors;treatments for CL/P were described;were case reports;the articles failed to fit in any of the above criteria but did not have CL/P candidate genes or related information.

Search methods to identify studies {#Sec5}
----------------------------------

Concepts included in the search were: CL/P, genetics (gene mutations), and humans. A combination of Medical Subject Headings (MeSH) terms and titles, abstracts, and keywords was used to develop the initial Medline search string, and then adapted to search the other databases. The last search date was May 28, 2018.

Study selection and data collection {#Sec6}
-----------------------------------

All the citations found in the search process were stored in RefWorks (ProQuest) and any duplicates were excluded. Search strategies and results were tracked using the Primary Excel Workbook designed for systematic reviews (<http://libguides.sph.uth.tmc.edu/excel_SR_workbook>). To check the reliability of study selection between the screeners, Cohen's Kappa test was performed using a randomly selected sample of 66 citations screened for CL/P-candidate genes by titles and abstracts. After achieving *a* \> 90% score for the Cohen's Kappa, all the titles and abstracts of the articles found through the database search were independently examined by two screeners. The full text of the articles not excluded in the above process was manually reviewed, and all results from the screening were recorded in the Primary Excel Workbook. The data collected were displayed as a descriptive narrative. A codebook for data extraction from eligible articles was developed, as described previously \[[@CR16]\]. The data elements extracted for the codebook included citation information, study level information (characteristics and results), and quality level information. The quality assessment of each study identified was performed using the Newcastle- Ottawa Scale (NOS), considering the selection criteria of pre- and post- fortification samples, comparability of these groups, and the ascertainment of either the exposure or outcome. NOS assigns a maximum score of 9 points where studies showing \< 5 points have high risk of bias and limitations, with these being excluded from a meta-analysis \[[@CR17]\].

Bioinformatics analysis of CL/P genes {#Sec7}
-------------------------------------

Functional enrichment analyses of the candidate genes were conducted using the pathway databases Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) through tools of the database for annotation, visualization, and integrated discovery (DAVID, version 6.8, <http://david.ncifcrf.gov>) \[[@CR18]\]. The enrichment of CL/P genes in a pathway or GO term was tested by the hypergeometric test implemented in DAVID. The *p*-values were adjusted by false discovery rate (FDR, *q*-value). The significant pathways were obtained by *q* \< 0.05 and at least four genes from the list of input genes (CL/P genes) in each pathway included. Hierarchical level 4 was used as the cutoff in order to avoid too general GO terms. The miRNA- mediated post-transcriptional regulation of the CL/P candidate genes was analyzed by using the following method: first, the miRNA-gene pairs were identified from three computationally predicted miRNA-target gene interaction databases, miRanda, PITA, and TargetScan \[[@CR19]--[@CR22]\]; then, the miRNA-gene pairs that were experimentally proofed were selected through miRTarbase analysis \[[@CR13]\]; finally, for each miRNA, the enrichment of CL/P candidate genes was examined using Fisher's Exact Test. To investigate which human phenotype terms are strongly enriched for the candidate genes, the WEB-based Gene SeT AnaLysis Toolkit (WebGestalt) (<http://webgestalt.org>) was used to perform the overrepresentation enrichment analysis (OEA) using the Human Phenotype Ontology (HPO) annotation database. The top 30 results from the OEA were retrieved on March 15, 2019. The minimum number of genes per category was set to 5 (default). The Benjamini--Hochberg procedure was used for multiple test correction \[[@CR23]\]. FDR values were used for all statistical analyses.

Genotype-phenotype association analysis {#Sec8}
---------------------------------------

Genotype-phenotype association analysis was conducted using GWAS available from dbGaP (dbGaP accession phs000774.v1.p1, <https://www.ncbi.nlm.nih.gov/gap>). This dbGaP repository includes 11,925 individuals from 4058 families, mostly from trios. Out of 11,925 individuals, 5327 were reported as Caucasians, 2221 as Asians, 473 as Africans, and 3904 were reported as having more than one ancestry. A total of 5008 individuals were reported as of Hispanic ethnicity. Not including the parents, 52% of children were males and 48% were females. Array-based genotypes from Illumina Infinium HumanCore Beadchips, including GWAS markers from HumanCore v1 with additional exome and custom contents from the Center for Craniofacial and Dental Genetics (CCDG) consortium, were analyzed with the PLINK software (version 1.90b) to test the association of each directly genotyped variant in the genes listed through the systematic review. Transmission disequilibrium test (TDT) was applied for maximizing analytical power for trios and for minimizing artifacts from population stratification.

Cell culture {#Sec9}
------------

Human lip fibroblasts were obtained from JCRB Cell Bank (\#JCRB9103KD) and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin, and L-glutamine. Human lip fibroblasts were plated onto 96-well cell culture plates at a density of 5000/well and treated with a mimic for either negative control, miR-124-3p, miR- 369-3p, miR- 374a-5p, miR-374b-5p, miR-497-5p, and miR-655-3p (mirVana miRNA mimic, ThermoFisher Scientific) using TransIT-X2 system (Mirus Bio LLC, Madison, WI), following the manufacturer's protocol (3 pmol mimic and 0.3 μl transfection reagent in 100 μl DMEM per well). Cell proliferation was determined using a cell counting kit 8 (Dojindo Molecular Technologies, Gaithersburg, MD) (*n* = 6 per group).

Quantitative RT-PCR {#Sec10}
-------------------

Total RNAs were isolated from cultured human lip fibroblasts treated with a mimic for target miRNAs for 1 day (n = 6 per group), using the QIAshredder and RNeasy mini extraction kit (QIAGEN), as previously described \[[@CR24]\]. The PCR primers used for quantitative RT-PCR are listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Statistical analysis {#Sec11}
--------------------

Two-tailed student's *t* tests were applied for the statistical analysis. A *p* value \< 0.05 was considered statistically significant. For all graphs, data are represented as mean ± standard deviation (SD).

Results {#Sec12}
=======

Literature search {#Sec13}
-----------------

Our systematic search identified a total of 5016 publications. After eliminating 2653 duplicates from the list, the remaining 2363 articles were further screened, using the titles and abstracts, independently by the two screeners, which resulted in 1558 publications being further excluded based on reasons such as referring to non-genetic studies and case reports. The remaining 748 articles were further assessed for eligibility through manual full-text review. Through this process, 393 articles satisfying all inclusion criteria were selected while 355 articles were excluded. These selected 393 studies were used for collection of CL/P-candidate genes and in the follow-up analyses (Fig. [1](#Fig1){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2).Fig. 1PRISMA flowchart for study selection. A graphical representation of the flow of citations reviewed in the course of the systematic review was provided using a PRISMA flow diagram

Summary of human CL/P genes {#Sec14}
---------------------------

We identified 172 CL/P-candidate genes from the qualified studies above (Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Tables S3--S8). For the bioinformatics analyses, we excluded phenotypic markers and genes with unknown genomic location. Among the CL/P-candidate genes, 10 genes were studied at least five times in different populations: *IRF6* (52 studies, encoding interferon regulatory factor 6, located at genomic locus 1q32.2), *MTHFR* (26 studies, encoding methylenetetrahydrofolate reductase, at 1p36.2), *TGFA* (18 studies, encoding transforming growth factor alpha, at 2q13.3), *MSX1* (25 studies, encoding msh homeobox 1, at 4p16.2), *TGFB3* (16 studies, encoding transforming growth factor beta 3, at 14q24.3), *NECTIN1* (10 studies, encoding Nectin cell adhesion molecule 1, at 11q23.3), *BMP4* (10 studies, encoding bone morphogenetic protein 4, at 14q22.2), *FOXE1* (6 studies, encoding forkhead box E1, at 9q22.33), *BCL3* (6 studies, encoding B-cell CLL/lymphoma 3, at 19q13.32), and *CRISPLD2* (5 studies, encoding cysteine rich secretory protein LCCL domain containing 2, at 16q24.1). Most of the gene mutations (168/177 = 94.9%) were reported only in non-syndromic CL/P while mutations in nine genes (*ADH1C*, *FGFR1*, *IRF6*, *MID1*, *NECTIN1*, *PHF8*, *SOX9*, *TGFA*, and *TP63*) were also reported in syndromic CL/P (9/177 = 5.1%). Several genes were reported only in syndromic cases; *CHD7* (CHARGE syndrome), *CR1* (van der Woude syndrome), *EFNB1* (craniofrontonasal syndrome), *KISS1R* (Kallmann syndrome), *MID1* (Opitz G/BBB syndrome), *REN* (van der Woude syndrome), and *SOX9* (Pierre-Robin syndrome). Mutations in eight genes (*BCL3*, *BMP4*, *IRF6*, *MSX1*, *MTHFR*, *NECTIN1*, *TGFA*, and *TGFB3*) were reported across different ethnic groups such as Caucasians, African Americans, Hispanics, and Asians, including but not limited to Chinese, Japanese, Indian, Turkish, Polish, Finnish, Brazilian, American, and European. By contrast, a total of 75 genes were reported as insignificant in some populations. For example, while mutations in *TGFA* were significant in the Iranian, Korean, Caucasian and Chilean population, they were not significant in the South American, Italian, Malaysian or Indian populations. Mutations in *IRF6* were not significant in some studies, but they were significant in larger studies in various populations (Additional file [1](#MOESM1){ref-type="media"}: Tables S3--S8). Recent advances in the discovery of genetic variants at whole genome level and the design of genome-wide approaches enable investigators to identify the involvement of multiple genes and loci in a single study (e.g., GWAS). Mutations in multiple genes and loci were reported in 87 and 12 studies, respectively. A significant association of *IRF6*, *MSX1* and *NECTIN1* with CL/P has been reported in several GWAS in different populations (Additional file [1](#MOESM1){ref-type="media"}: Table S4). However, no significant association was reported in several studies conducted in Danish, Mesoamerican, and African populations for *IRF6*, American and Latvian populations for *MSX1*, and Taiwanese population for *NECTIN1* (Additional file [1](#MOESM1){ref-type="media"}: Table S6).Table 1Summary of genes associated with cleft lip with/without cleft palate in humansGene symbolGene nameLociSyndromic/ NonsyndromicABCA4ATP binding cassette subfamily A member 41p22.1NonsyndromicABCB1ATP binding cassette subfamily B member 17q21.12NonsyndromicADAM3AADAM metallopeptidase domain 3A8p11.22NonsyndromicACSS2Acyl-coenzyme A synthetase short-chain family member 220q11.22NonsyndromicADAM5ADAM metallopeptidase domain 58p11.22NonsyndromicADAMTS20ADAM metallopeptidase with thrombospondin type 1 motif 2012q12NonsyndromicADGRL2Adhesion G protein-coupled receptor L21p31.1NonsyndromicADH1CAlcohol dehydrogenase 1C (class I), gamma polypeptide4q23Nonsyndromic & Syndromic: Fetal alcohol syndromeAQP7Aquaporin 79p13.3NonsyndromicARHGAP29Rho GTPase activating protein 291p22.1NonsyndromicASS1Argininosuccinate synthase 19q34.11NonsyndromicAXIN2Axin 217q24.1NonsyndromicBAG4BCL2 associated athanogene 48p11.23NonsyndromicBCL3B-cell CLL/lymphoma 319q13.32NonsyndromicBHMT2Betaine-homocysteine S-methyltransferase 25q14.1NonsyndromicBLMBloom syndrome RecQ like helicase15q26.1NonsyndromicBMP4Bone morphogenetic protein 414q22.2NonsyndromicBMPR1BBone morphogenetic protein receptor type 1B4q22.3NonsyndromicBRIP1BRCA1 interacting protein C-terminal helicase 117q23.2NonsyndromicCBSCystathionine-beta-synthase21q22.3NonsyndromicCDH1Cadherin 116q22.1NonsyndromicCDH2Cadherin 218q12.1NonsyndromicCENPJCentromere protein J13q12.12-q12.13NonsyndromicCHD7Chromodomain helicase DNA binding protein 78q12.2Syndromic: CHARGE syndromeCLPTM1CLPTM1, transmembrane protein19q13.32NonsyndromicCOL4A2Collagen type IV alpha 2 chain13q34NonsyndromicCOL4A3Collagen type IV alpha 3 chain2q36.3NonsyndromicCOL4A4Collagen type IV alpha 4 chain2q36.3NonsyndromicCOL21A1Collagen type XXI alpha 1 chain6p12.1; 6p12.3-p11.2NonsyndromicCR1Complement C3b/C4b receptor 1 (Knops blood group)1q32.2Syndromic: Van der Woude syndromeCRISPLD2Cysteine rich secretory protein LCCL domain containing 216q24.1NonsyndromicCYP1A1Cytochrome P450 family 1 subfamily A member 115q24.1NonsyndromicCYP2E1Cytochrome P450 family 2 subfamily E member 110q26.3NonsyndromicDCAF7DDB1 and CUL4 associated factor 717q23.3NonsyndromicDHFRDihydrofolate reductase5q14.1NonsyndromicDICER1Dicer 1, ribonuclease III14q32.13NonsyndromicDLX1Distal-less homeobox 12q31.1NonsyndromicDMDDystrophinXp21.2-p21.1NonsyndromicDVL2Dishevelled segment polarity protein 217p13.1NonsyndromicE2F1E2F transcription factor 120q11.22NonsyndromicEFNB1Ephrin B1Xq13.1Syndromic: Craniofrontonasal syndromeEIF2B3Eukaryotic translation initiation factor 2B subunit gamma1p34.1NonsyndromicEGF61Epidermal growth factor 614q25NonsyndromicESRRGEstrogen related receptor gamma1q41NonsyndromicEVCEvC ciliary complex subunit 14p16.2NonsyndromicEVC2EvC ciliary complex subunit 24p16.2NonsyndromicEYA1EYA transcriptional coactivator and phosphatase 18q13.3NonsyndromicF13A1Coagulation factor XIII A chain6p25.1NonsyndromicFAM49AFamily with sequence similarity 49 member A2p24.2NonsyndromicFGF1Fibroblast growth factor 15q31.3NonsyndromicFGF2Fibroblast growth factor 24q28.1NonsyndromicFGF3Fibroblast growth factor 311q13.3NonsyndromicFGF10Fibroblast growth factor 105p12NonsyndromicFGF18Fibroblast growth factor 185q35.1NonsyndromicFGFR1Fibroblast growth factor receptor 18p11.23Nonsyndromic & Syndromic: Kallmann syndromeFGFR2Fibroblast growth factor receptor 210q26.13NonsyndromicFOXE1Forkhead box E19q22.33NonsyndromicFOXF2Forkhead box F26p25.3NonsyndromicFOXG1Forkhead box G114q12NonsyndromicFOXP2Forkhead box protein P27q31.1NonsyndromicFZD6Frizzled class receptor 68q22.3NonsyndromicGABRB3Gamma-aminobutyric acid type A receptor beta 3 subunit15q12NonsyndromicGAD1Glutamate decarboxylase 12q31.1NonsyndromicGCH1GTP cyclohydrolase 114q22.2NonsyndromicGLI2GLI family zinc finger 22q14.2NonsyndromicGREM1Gremlin 1, DNA family BMP antagonist15q13.3NonsyndromicGSTM1Glutathione S-transferase mu 11p13.3NonsyndromicGSTP1Glutathione S-transferase pi 111q13.2NonsyndromicGSTT1Glutathione S-transferase theta 122q11.23NonsyndromicHECTD1HECT domain E3 Ubiquitin protein ligase 114q12NonsyndromicHKDC1Hexokinase domain containing 110q22.1NonsyndromicIRF6Interferon regulatory factor 61q32.2NonsyndromicJAG2Jagged214q32.33NonsyndromicJARID2Jummonji and AT-rich interaction domain containing 26p22.3NonsyndromicKIF2AKinesin family member 2A5q12.1NonsyndromicKIF7Kinesin family member 715q26.1NonsyndromicKISS1RKISS1 receptor19p13.3Syndromic: Kallmann syndromeKRT18Keratin 1812q13.13NonsyndromicLACTBLactamase beta15q22.2NonsyndromicLHX8LIM homeobox 81p31.1NonsyndromicLPHN2Adhesion G protein-coupled receptor L21p31.1NonsyndromicMAFBMAF bZIP transcription factor B20q12NonsyndromicMGAMMaltase-glucoamylase7q34NonsyndromicMID1Midline 1Xp22.2Nonsyndromic & Syndromic: Opitz G/BBB syndromeMMP3Matrix metallopeptidase 311q22.2NonsyndromicMMP9Matrix metallopeptidase 920q13.12NonsyndromicMROH7Maestro heat like repeat family member 71p32.3NonsyndromicMRPL53Mitochondrial ribosomal protein L532p13.1NonsyndromicMSX1msh homeobox 14p16.2NonsyndromicMSX2msh homeobox 25q35.2NonsyndromicMTR5-methyltetrahydrofolate-homocysteine methyltransferase1q43NonsyndromicMTRR5-methyltetrahydrofolate-homocysteine methyltransferase reductase5p15.31NonsyndromicMYH9Myosin heavy chain 922q12.3NonsyndromicMTHFD1Methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 114q23.3NonsyndromicMTHFRMethylenetetrahydrofolate reductase1p36.22NonsyndromicNAT1N-acetyltransferase 18p22NonsyndromicNAT2N-acetyltransferase 28p22NonsyndromicNECTIN1Nectin cell adhesion molecule 111q23.3NonsyndromicNECTIN2Nectin cell adhesion molecule 219q13.32NonsyndromicNECTIN3Nectin cell adhesion molecule 33q13.13NonsyndromicNOGNoggin17q22NonsyndromicNTN1Netrin 117p13.1NonsyndromicOFC1Orofacial cleft 16p24NonsyndromicOFC2Orofacial cleft 22p14-p13NonsyndromicPAHPhenylalanine hydroxylase12q23.2NonsyndromicPARVAParvin alpha11p15.3NonsyndromicPTCH1Patched 19q22.32NonsyndromicPAX3Paired box 32q36.1NonsyndromicPAX7Paired box 71p36.13NonsyndromicPAX9Paired box 914q13.3NonsyndromicPCYT1APhosphate cytidylyltransferase 1, choline, alpha3q29NonsyndromicPDGFCPlatelet derived growth factor C4q32.1NonsyndromicPEMTPhosphatidylethanolamine N-methyltransferase17p11.2NonsyndromicPKP1Plakophilin 11q32.1NonsyndromicPHF8PHD finger protein 8Xp11.22NonsyndromicPHYHPhytanoyl-CoA 2-hydroxylase10p13NonsyndromicRPS26Ribosomal Protein S2612q13.2NonsyndromicPRSS1Protease, serine 17q34NonsyndromicPRSS35Protease, serine 356q14.2NonsyndromicRAD51RAD51 recombinase15q15.1NonsyndromicRAD54BRAD54 homolog B8q22.1NonsyndromicRARARetinoic Acid Receptor Alpha17q21.2NonsyndromicRECQL5RecQ like helicase 517q25.1NonsyndromicREG3ARegenerating family member 3 alpha2p12NonsyndromicRENRenin1q32.1Syndromic: Van der Woude syndromeRFC1Replication factor C subunit 14p14NonsyndromicRHPN2Rhophilin Rho GTPase binding protein 219q13.11NonsyndromicRUNX2Runt related transcription factor 26p21.1NonsyndromicRYKReceptor-like tyrosine kinase3q22.2NonsyndromicSATB2SATB homeobox 22q33.1NonsyndromicSEC16ASEC 16 homolog A, endoplasmic reticulum export factor9q34.3NonsyndromicSERPINA6Serpin family A member 614q32.13NonsyndromicSLC6A4Solute carrier family 6 member 417q11.2NonsyndromicSMAD1SMAD family member 14q31.21NonsyndromicSMAD2SMAD family member 218q21.1NonsyndromicSOX9SRY-box 917q24.3Syndromic: Pierre-Robin SyndromeSPRY1Sprouty RTK signaling antagonist 14q28.1NonsyndromicSUMO1Small ubiquitin-like modifier 12q33.1NonsyndromicSTK32BSerine/threonine kinase 32B4p16.2NonsyndromicSYNE3Spectrin repeat containing nuclear envelop family member 314q32.13NonsyndromicTAF1BTATA-box binding protein associated factor, RNA polymerase I subunit B2p25.1NonsyndromicTANC2Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 217q23.2-q23.3NonsyndromicTBX22T-box 22Xq21.1NonsyndromicTCN2Transcobalamin 222q12.2NonsyndromicTEX11Testis expressed 11Xq13.1NonsyndromicTFAP2ATranscription factor AP-2 alpha6p24.3NonsyndromicTGFATransforming growth factor alpha2p13.3NonsyndromicTGFB1Transforming growth factor beta 12p13.3NonsyndromicTGFB2Transforming growth factor beta 21q41NonsyndromicTGFB3Transforming growth factor beta 314q24.3NonsyndromicTIMP2TIMP metallopeptidase inhibitor 217q25.3NonsyndromicTMEM19transmembrane protein 1912q21.1NonsyndromicTNS1Tensin 12q35NonsyndromicTOX3TOX high mobility group box family member 316q12.1NonsyndromicTP63Tumor protein p633q28Syndromic: Hay wells or AEC syndromeTPH2Tryptophan hydroxylase 212q21.1NonsyndromicTPM1Tropomyosin 1 (alpha)15q22.2NonsyndromicTULP4Tubby like protein 46q25.3NonsyndromicTYMSThymidylate synthase18p11.32NonsyndromicVAX1Ventral anterior homeobox 110q25.3NonsyndromicVAX2Ventral anterior homeobox 22p13.3NonsyndromicVWA8Von Willebrand factor A domain-containing protein 813q14.11NonsyndromicWNT3Wnt family member 317q21.31-q21.32NonsyndromicWNT3AWnt family member 3A1q42.13NonsyndromicWNT5AWnt family member 5A3p14.3NonsyndromicWNT5BWnt family member 5B12p13.33NonsyndromicWNT6Wnt family member 62q35NonsyndromicWNT9BWnt family member 9B17q21.32NonsyndromicWNT10AWnt family member 10A2q35NonsyndromicWNT11Wnt family member 1111q13.5NonsyndromicYOD1TOD1 deubiquitinase1q32.1NonsyndromicZNF385BZinc finger protein 385B2q31.2-q31.3NonsyndromicDue to space limits, the details (e.g. publication ID) of each gene were not provided in this table

GO term enrichment analysis {#Sec15}
---------------------------

We analyzed CL/P genes enriched in the GO terms to assess the functional features of CL/P genes (Additional file [1](#MOESM1){ref-type="media"}: Tables S9--S12). The most specific enriched terms among GO biological processes showed strong association with development and morphogenesis of other organs (Additional file [1](#MOESM1){ref-type="media"}: Tables S9 and S10). These results suggest that CL/P genes may potentially cause additional developmental disorders while 70% of CL/P cases are non-syndromic without any additional birth defects. In non-syndromic CL/P cases, molecules that are specifically expressed in the lip region during lip formation may help explain the molecular mechanism in regard to how only lip formation is affected. Lip formation involves the growth and fusion of maxillary and nasal processes during embryogenesis \[[@CR25]\]. We identified a strong association with positive and negative regulators of several cellular processes, including cell proliferation, apoptosis, differentiation, and epithelial-to-mesenchymal transition. We also found that genes involved in folic acid metabolic process were significantly enriched (7 CL/P genes) (Additional file [1](#MOESM1){ref-type="media"}: Table S10). The current approach for the prevention of neural tube defects and CL/P is folic acid supplementation \[[@CR26]\]. Our results suggest that some individuals with CL/P have defects in folic acid metabolism, and that a folic acid supplement can potentially prevent CL/P.

Among the enriched GO terms in its domain Molecular Function (MF) (Additional file [1](#MOESM1){ref-type="media"}: Tables S9 and S11), we observed enrichment of several terms related to molecular binding: transcription factor activity, sequence-specific binding (28 CL/P genes), sequence-specific DNA binding (23 CL/P genes), chromatin binding (16 CL/P genes), and binding to Frizzled, a family of G protein-coupled receptors for WNT ligands (11 CL/P genes). The remaining enriched terms in the MF domain included: protein homodimerization activity (26 CL/P genes); growth factor activity (13 CL/P genes), which is induced by FGF, BMP, TGFβ and PDGF; protein tyrosine kinase activity (10 CL/P genes), 1- phosphatidylinositol-3 kinase activity (8 CL/P genes), and phosphatidylinositol-4,5-bisphosphate 3-kinase activity (8 CL/P genes) induced by FGF signaling; and others. Thus, the GO MF term analysis highlighted the contribution of morphologic factors involved in WNT, FGF, BMP, TGFβ, and PDGF signaling pathways.

Among GO terms representing cellular components (Additional file [1](#MOESM1){ref-type="media"}: Tables S9 and S12), most terms were enriched in extracellular components: extracellular region (48 CL/P genes), extracellular space (36 CL/P genes), cell surface (27 CL/P genes), and proteinaceous extracellular matrix (ECM) (22 CL/P genes). In GO terms, many growth factors including WNT, FGF, BMP, TGFβ, and PDGF and their extracellular regulators (e.g. ECM) were identified in these groups. These findings are in agreement with the fact that growth factors are activated in the extracellular space.

Human phenotype ontology enrichment analysis {#Sec16}
--------------------------------------------

We used the HPO database to investigate which human phenotype terms were enriched for the identified set of CL/P candidate genes. The most enriched phenotypic term was abnormal number of teeth (28 genes), followed by CL (23 genes), cleft upper lip (22 genes), reduced number of teeth (25 genes), and oral cleft (36 genes) (Additional file [1](#MOESM1){ref-type="media"}: Table S13). Among the top 30 results, most phenotypes were directly related to CL/P, congenital dental disorders, or congenital abnormalities of the fingers.

KEGG pathway analysis {#Sec17}
---------------------

We hypothesized that CL/P genes share common features among wide arrays of biological functions and pathways. We therefore examined which biological pathways were enriched with CL/P genes by using the DAVID bioinformatics tool and the canonical pathways from the KEGG database (Additional file [1](#MOESM1){ref-type="media"}: Table S14). The regulatory pathway annotation was performed based on the score and visualization of the pathways used in the KEGG database. Among the cellular functions in KEGG pathways, 19 pathways were statistically significant in the enrichment of CL/P genes (FDR \< 5%). Seven of these pathways were related to cancer: pathways in cancer (43 CL/P genes), basal cell carcinoma (16 CL/P genes), proteoglycans in cancer (16 CL/P genes), melanoma (10 CL/P genes), pancreatic cancer (8 CL/P genes), bladder cancer (6 CL/P genes), and colorectal cancer (7 CL/P genes). Previous population-based studies suggest that individuals with CL/P have a higher risk of cancer in the breast, brain, and lung later in life \[[@CR27]--[@CR29]\]. Among them, molecules related to Hippo, FGF, WNT, and TGFβ signaling are highlighted in these cancer-related pathways. These cellular signaling pathways were significantly involved in CL/P: Hippo signaling pathway (22 CL/P genes), signaling pathways regulating pluripotency of stem cells (21 CL/P genes), phosphoinositide 3-kinase (PI3K)- Akt signaling pathway (15 CL/P genes), mitogen-activated protein kinase (MAPK) signaling pathway (13 CL/P genes), WNT signaling pathway (11 CL/P genes), and TGF-β signaling pathway (9 CL/P genes).

Genotype-phenotype association analysis {#Sec18}
---------------------------------------

To determine the contribution of genetic variations to CL/P, a genotype-phenotype association analysis was conducted using GWAS for the genetics of orofacial clefts and related phenotypes (e.g. CL/P) available from dbGaP (dbGaP accession phs000774.v1.p1). By PLINK analysis, we identified 2975 cases vs 8751 controls out of 11,925 individuals. We investigated whether single nucleotide polymorphisms (SNPs) mapped to the CL/P-candidate genes are associated with human CL/P phenotypes using TDT of The Genetics of Orofacial Clefts and Related Phenotypes GWAS dataset. This method is appropriate for statistical imbalances between transmitted and non-transmitted alleles in parent-child trios. We investigated all directly genotyped (i.e. not imputed) variants within the genes found in the systematic review. A total of 5437 variants from 179 genes were included in the association analysis, while some genes did not have the genotyped SNPs in this dataset and some SNPs did not present any variations in the analyzed samples. Because most SNPs in the same gene have strong linkage disequilibrium, we set our candidate-wise significance threshold at 2.79 × 10^− 4^ by using the Bonferroni level with the number of genes tested (0.05/179). We identified 56 SNPs from 12 genes with *p*-values smaller than 2.79 × 10^− 4^ (Table [2](#Tab2){ref-type="table"}). The top association signals were from *IRF6* and *NTN1* (Netrin 1), which also showed nominal genome-wide significance in the GWAS dataset (*p* \< 5 × 10^− 8^). We also observed gene-wide significant signals (*p* \< 2.5 × 10^− 6^) from *ABCA4* (ATP-binding cassette, sub-family A, member 4) and *PAX7* (paired box 7). Although *ADAM3A* (ADAM metallopeptidase domain 3A), *FOXE1* (forkhead box E1), *MSX2* (msh homeobox 2), *MTHFR* (methylenetetrahydrofolate reductase), *TP63* (tumor protein p63), *TPM1* (tropomyosin 1), *VAX1* (ventral anterior homeobox 1), and *WNT9B* (wingless-type MMTV integration site family, member 9B) did not reach the genome-wide nor gene-wide significance thresholds, these genes reached candidate-wise significance level (*p* \< 2.79 × 10^− 4^).Table 2Genotype-phenotype associationTop markerTypeGene*p*-valuers1044516UTR3*IRF6*2.66 × 10^−9^rs1880646Intron*NTN1*3.02 × 10^−9^rs4147827Intron*ABCA4*8.51 × 10^−7^rs742071Intron*PAX7*2.09 × 10^−6^rs6474148Intron*ADAM3A*3.26 × 10^−6^rs1443435UTR3*FOXE1*1.39 × 10^−5^rs6585429Intron*VAX1*2.28 × 10^−5^rs2066462Silent*MTHFR*7.38 × 10^−5^rs3803499Intron*TPM1*1.91 × 10^−4^rs1515497Intron*TP63*2.19 × 10^−4^rs14459UTR3*MSX2*2.34 × 10^−4^rs4968282Intron*WNT9B*2.65 × 10^−4^

Environmental and epigenetic factors {#Sec19}
------------------------------------

In addition to gene mutations, genetic background such as ethnicity, population and gender have substantial influence on the birth prevalence of CL/P. Environmental factors such as maternal age, smoking, alcohol consumption, obesity, and micronutrient deficiencies are known to be strong susceptibility risk factors. Recent studies suggest that environmental factors can interact with the epigenetic system and control gene expression at the post- transcriptional level \[[@CR30]--[@CR32]\]. To explore the degree to which miRNAs regulate the expression of CL/P genes, we performed a bioinformatics analysis to identify miRNAs whose target genes are statistically enriched with CL/P genes (Table [3](#Tab3){ref-type="table"}). By applying the adjusted *p*-value (FDR) \< 0.1, a total of 16 miRNAs were significantly enriched with the targeted CL/P genes. These 16 miRNAs were categorized into 10 known and one unknown miRNA families: the miR-27 family (hsa-miR- 27b- 3p, 23 CL/P genes), miR-124 family (hsa- miR- 124-3p, 29 CL/P genes), miR-154 family (hsa-miR-369-3p, 13 CL/P genes; hsa- miR-655-3p, 14 CL/P genes; hsa-miR-300, 18 CL/P genes; hsa-miR-381-3p, 18 CL/P genes), miR-203 family (hsa-miR-203a-3p, 9 CL/P genes), miR-368 family (hsa-miR-376b-3p, 10 CL/P genes), miR-374 family (hsa-miR- 374a-5p, 22 CL/P genes; hsa-miR-374b-5p, 22 CL/P genes), miR-497 family (hsa-miR-497-5p, 25 CL/P genes), miR-503 family (hsa-miR-503-5p, 10 CL/P genes), miR-550 family (hsa-miR-550a-5p, 5 CL/P genes; hsa-miR-550a-3-5p, 5 CL/P genes), miR-1271 family (hsa-miR-1271-3p, 5 CL/P genes), and an unknown family (hsa-miR-3678-3p, 5 CL/P genes). Notably, except for hsa-miR-27b-3p \[[@CR33]\], these miRNAs have not yet been reported in CL/P. In the enrichment analysis, CL/P genes regulated by multiple miRNAs were: *EN2* (targeted by 6 miRNA families), *FZD6* (targeted by 5 miRNA families), *HECTD1* (targeted by 5 miRNA families), and *YOD1* (targeted by 5 miRNA families) (Table [4](#Tab4){ref-type="table"}). Because gene expression of *EN2*, *FZD6*, *HECTD1*, and *YOD1* is regulated by several miRNAs, expression of these genes may be more susceptible to environmental factors during lip formation.Table 3MicroRNA (miRNA) enrichment analysis of 161 human CL/P genes (FDR \< 0.1)miRNA family IDmiRNA nameGene symbolFDR (BH)miR-154hsa-miR-369-3p*CHD7*, *DMD*, *EYA1*, *GABRB3*, *GREM1*, *HOXB3*, *NOG*, *PAX6*, *TIMP2*, *TULP4*, *BAG4*, *FZD6*, *YOD1*0.03miR-154hsa-miR-655-3p*BCL2*, *DMD*, *EN2*, *GREM1*, *HOXB3*, *MAFB*, *MID1*, *NTN1*, *PAX6*, *SATB2*, *TULP4*, *CYP1A1*, *FZD6*, *YOD1*0.03miR-374hsa-miR-374a-5p*CHD7*, *DMD*, *EYA1*, *FGFR2*, *FOXG1*, *HECTD1*, *HOXB3*, *JARID2*, *MSX1*, *NOG*, *NTN1*, *PAX6*, *RAD51*, *RHPN2*, *RUNX2*, *TGFA*, *TNS1*, *WNT5A*, *WNT5B*, *YOD1*, *EN2*, *FZD6*0.07miR-374hsa-miR-374b-5p*CHD7*, *DMD*, *EYA1*, *FGFR2*, *FOXG1*, *HECTD1*, *HOXB3*, *JARID2*, *MSX1*, *NOG*, *NTN1*, *PAX6*, *RAD51*, *RHPN2*, *RUNX2*, *TGFA*, *TNS1*, *WNT5A*, *WNT5B*, *YOD1*, *EN2*, *FZD6*0.07miR-497hsa-miR-497-5p*AXIN2*, *BAG4*, *BCL2*, *CHD7*, *CRISPLD2*, *EN2*, *EYA1*, *FGF1*, *FGF2*, *FGFR1*, *FGFR2*, *FOXP2*, *FZD6*, *HECTD1*, *JARID2*, *PAX7*, *RHPN2*, *SATB2*, *SLC6A4*, *WNT3A*, *YOD1*, *MTHFR*, *RUNX2*, *TFAP2A*, *TPM1*0.07miR-124hsa-miR-124-3p*GABRB3*, *GCH1*, *JAG2*, *KIF2A*, *MTR*, *MYH9*, *ROR2*, *RYK*, *TANC2*, *ARHGAP29*, *COL4A4*, *DVL2*, *EFNB1*, *FGF1*, *FGFR1*, *FOXF2*, *GREM1*, *HOXB3*, *KIF7*, *PDGFC*, *PEMT*, *PKP1*, *RAD51*, *RUNX2*, *SOX9*, *TBX22*, *TP63*, *TPM1*, *WNT5B*0.09miR-1271hsa-miR-1271-3p*CBS*, *DCAF7*, *FZD6*, *RAD51*, *YOD1*0.09miR-203hsa-miR-203a-3p*E2F1*, *EN2*, *GREM1*, *HECTD1*, *KIF2A*, *PAX6*, *RUNX2*, *SMAD2*, *TP63*0.09miR-27hsa-miR-27b-3p*BCL3*, *CHD7*, *COL21A1*, *DVL2*, *EN2*, *EYA1*, *FGF1*, *FOXP2*, *GABRB3*, *GCH1*, *GREM1*, *HOXB3*, *PAX9*, *RARA*, *SATB2*, *SMAD1*, *STK32B*, *SMAD2*, *DCAF7*, *PAX3*, *PAX7*, *SEC16A*, *WNT9B*0.09miR-154hsa-miR-300*CR1*, *DVL2*, *FGF1*, *FGFR2*, *FOXF2*, *FOXP2*, *GABRB3*, *GAD1*, *HECTD1*, *JAG2*, *MID1*, *PDGFC*, *TANC2*, *TGFB3*, *WNT5A*, *CRISPLD2*, *GREM1*, *PHF8*0.09NAhsa-miR-3678-3p*E2F1*, *GABRB3*, *JARID2*, *SLC6A4*, *YOD1*0.09miR-368hsa-miR-376b-3p*CRISPLD2*, *EN2*, *FGFR1*, *MYH9*, *PAX3*, *PAX6*, *PRSS35*, *TANC2*, *FGF2*, *FOXG1*0.09miR-154hsa-miR-381-3p*CR1*, *DVL2*, *FGF1*, *FGFR2*, *FOXF2*, *FOXP2*, *GABRB3*, *GAD1*, *HECTD1*, *JAG2*, *MID1*, *PDGFC*, *TANC2*, *TGFB3*, *WNT5A*, *CRISPLD2*, *GREM1*, *PHF8*0.09miR-503hsa-miR-503-5p*HECTD1*, *JARID2*, *MAFB*, *WNT3A*, *BCL2*, *DHFR*, *FGF2*, *FGFR1*, *SMAD2*, *TFAP2A*0.09miR-550hsa-miR-550a-3-5p*CBS*, *DCAF7*, *FZD6*, *RAD51*, *YOD1*0.09miR-550hsa-miR-550a-5p*CBS*, *DCAF7*, *FZD6*, *RAD51*, *YOD1*0.09*BH* Benjamini--Hochberg adjustment for multiple test correction \[[@CR23]\]Table 4Human CL/P genes targeted by at least two microRNA (miRNA) familiesGene\# miRNA familiesmiRNA family*EN2*6miR-154, miR-203, miR-27, miR-368, miR-374, miR-497*YOD1*5miR-1271, miR-154, miR-374, miR-497, miR-550*FZD6*5miR-1271, miR-154, miR-374, miR-497, miR-550*HECTD1*5miR-154, miR-203, miR-374, miR-497, miR-503*GREM1*4miR-124, miR-154, miR-203, miR-27*HOXB3*4miR-124, miR-154, miR-27, miR-374*PAX6*4miR-154, miR-203, miR-368, miR-374*RAD51*4miR-124, miR-1271, miR-374, miR-550*CHD7*4miR-154, miR-27, miR-374, miR-497*EYA1*4miR-154, miR-27, miR-374, miR-497*RUNX2*4miR-124, miR-203, miR-374, miR-497*FGF1*4miR-124, miR-154, miR-27, miR-497*FGFR1*4miR-124, miR-368, miR-497, miR-503*GABRB3*3miR-124, miR-154, miR-27*FGFR2*3miR-154, miR-374, miR-497*JARID2*3miR-374, miR-497, miR-503*CRISPLD2*3miR-154, miR-368, miR-497*FOXP2*3miR-154, miR-27, miR-497*TANC2*3miR-124, miR-154, miR-368*DVL2*3miR-124, miR-154, miR-27*DCAF7*3miR-1271, miR-27, miR-550*BCL2*3miR-154, miR-497, miR-503*SATB2*3miR-154, miR-27, miR-497*FGF2*3miR-368, miR-497, miR-503*SMAD2*3miR-203, miR-27, miR-503*DMD*2miR-154, miR-374*WNT5A*2miR-154, miR-374*NOG*2miR-154, miR-374*NTN1*2miR-154, miR-374*FOXG1*2miR-368, miR-374*RHPN2*2miR-374, miR-497*WNT5B*2miR-124, miR-374*JAG2*2miR-124, miR-154*FOXF2*2miR-124, miR-154*PDGFC*2miR-124, miR-154*CBS*2miR-1271, miR-550*BAG4*2miR-154, miR-497*MAFB*2miR-154, miR-503*PAX7*2miR-27, miR-497*WNT3A*2miR-497, miR-503*TFAP2A*2miR-497, miR-503*TPM1*2miR-124, miR-497*GCH1*2miR-124, miR-27*KIF2A*2miR-124, miR-203*MYH9*2miR-124, miR-368*TP63*2miR-124, miR-203*PAX3*2miR-27, miR-368

Experimental validation {#Sec20}
-----------------------

miRNA regulates expression of its genes anti- correlationally \[[@CR34]\]. To test whether induction of potential CL/P-candidate miRNAs caused proliferation defects through the suppression of target gene expression, we treated cultured human lip fibroblasts with each miRNA mimic. The miR-497-5p and miR-655-3p mimics were most significantly inhibited cell proliferation in human lip fibroblasts (Fig. [2](#Fig2){ref-type="fig"}a). To identify target genes regulated by either miR-497-5p or miR-655-3p, we performed quantitative RT-PCR analyses for the predicted target genes (*AXIN2*, *BAG4*, *BCL2*, *CHD7*, *CRISPLD2*, *EN2*, *EYA1*, *FGF1*, *FGF2*, *FGFR1*, *FGFR2*, *FOXP2*, *FZD6*, *HECTD1*, *JARID2*, *MTHFR*, *PAX7*, *RHPN2*, *RUNX2*, *SATB2*, *SLC6A4*, *TFAP2A*, *TPM1*, *WNT3A*, and *YOD1* for miR-497-5p; and *BCL2*, *CYP1A1*, *DMD*, *EN2*, *FZD6*, *GREM1*, *HOXB3*, *MAFB*, *MID1*, *NTN1*, *PAX6*, *SATB2*, *TULP4*, and *YOD1* for miR-655-3p) in human lip fibroblasts after treatment with mimics of either miR-497-5p or miR-655-3p. The expression of almost target genes except *EN2*, *GREM1*, *MAF6*, *TULP4* and *YOD1* was significantly downregulated by treatment with miR- 655-3p mimic (Fig. [2](#Fig2){ref-type="fig"}b). The expression of target genes (*BAG4*, *CHD7*, *CRISPLD2*, *FGFR1*, *FOXP2*, *HECTD1*, *RUNX2*, and *TFAP2A*) was significantly downregulated by treatment with miR-497-5p mimic (Fig. [2](#Fig2){ref-type="fig"}c). *PAX6* was excluded because its expression is restricted in the anterior ectoderm during early embryogenesis and the ectoderm of craniofacial surface during craniofacial development \[[@CR35]--[@CR37]\]. *EYA1* expression was unexpectedly increased after treatment with miR-497-5p mimic.Fig. 2Experimental validation of predicted miRNAs. **a** Cell proliferation assays in human lip fibroblasts treated with the indicated mimics of miRNAs. Negative control (control, light blue), miR-369-3p (orange), miR-655-3p (gray), miR-374a-3p (yellow), miR-374b-3p (blue), miR-497-5p (light green), and miR-124-3p (dark blue). \*\*\* *p* \< 0.001. **b** Quantitative RT-PCR for the indicated genes after treatment with negative control (light blue) or miR-655-3p mimic (orange). \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001. **c** Quantitative RT-PCR for the indicated genes after treatment with negative control (light blue) or miR-497-5p mimic (orange). \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001

Discussion {#Sec21}
==========

Orofacial cleft is described in approximately 400 known human syndromes \[[@CR38]--[@CR40]\]. Several factors have been implicated in clefting by studies of mouse models \[[@CR25]\] and genetic screening in humans. Our literature search identified 177 genes as possible causative genes of CL/P. Our follow-up bioinformatics analysis could group genes by common features of CL/P genes in function, pathway, and miRNA regulation. As expected, the contribution of most of the highlighted pathways (e.g. FGF, Hippo, TGFβ, and WNT) to the growth and developmental process has been shown in previous mouse genetic studies for craniofacial development \[[@CR25]\]. Cellular metabolic pathways such as one-carbon metabolism are also highlighted in KEGG pathway analysis. The one-carbon metabolism, mediated by the folate cofactor, is involved in multiple physiological processes including biosynthesis of purines and thymidine, amino acid homeostasis, epigenetic maintenance, and redox defense \[[@CR41]\]. Mice with one-carbon metabolic aberrations (*Mthfd1l*^*−/−*^ mice) are embryonic lethal by E12.5, with craniofacial deformities including midfacial cleft \[[@CR41]\]. However, in human studies it is still controversial in the significance of genetic mutations in genes involved in one-carbon metabolism \[[@CR42]--[@CR45]\]; further studies are necessary to reach to the conclusive evidence.

Multiple processes synthesize miRNAs and then transcribe them as long primary transcripts that are cleaved by Dicer, a type 3 ribonuclease, to produce mature, functional miRNAs. In human genetic studies, the increasing number of studies show functional significance of single- nucleotide polymorphisms (SNPs) in genes related to CL/P \[[@CR46]--[@CR50]\]. These SNPs might alter the binding activity of miRNAs. For example, previous studies show that SNPs in the miRNA-binding sites of *MSX1*, *FGF2*, *FGF5* and *FGF9* are associated with the susceptibility of nonsyndromic orofacial clefts \[[@CR51], [@CR52]\]. A recent study shows that plasma miRNAs are differentially expressed in nonsyndromic CP and nonsyndromic CL/P \[[@CR53]\]. The miRNAs may also systemically regulate gene expression during embryogenesis, while some miRNAs may uniquely regulate gene expression in some particular tissues with an interaction with mRNAs expressed in a tissue-specific manner. In mice, loss of *Dicer* results in absence of mature miRNAs and, therefore, the phenotype in *Dicer* knockout mice reflects how important miRNAs are for proper development. Interestingly, cranial neural crest (CNC) cell- specific *Dicer* knockout (*Dicer*^*F/F*^*;Wnt1-Cre*) mice, but not epithelial-specific *Dicer* knockout (*Dicer*^*F/F*^*;K14-Cre*) mice, exhibit severe midfacial deformities resulting from decreased cell proliferation and increased apoptosis in the developing craniofacial regions \[[@CR54]--[@CR57]\], indicating that miRNAs have crucial roles in the fate determination of CNC cells during midfacial development \[[@CR54]--[@CR57]\]. In this study, to evaluate the function of each miRNA in cell proliferation/survival, we employed human lip fibroblasts, CNC-derived cells, for our experimental validation. The functional significance of candidate miRNAs were tested in cell proliferation/survival assays in cultured human lip fibroblasts. We found that miR-369-3p, miR-655-3p, miR-374a-5p, miR-374b-5p, and miR-497-5p that were first identified in this study as candidates involved in human CL/P suppressed cell proliferation in cultured human lip fibroblasts. Top two candidate miRNAs, miR-655-3p and miR-497-5p, were further tested in the miRNA-gene regulation assay. We found that these miRNA mimics suppressed expression of genes associated with human CL/P. Thus, the miRNAs predicted were successfully validated in our experiments. Taken together, this study provides a better understanding of CL/P as well as data that will be available for the future research of genetic approaches used to characterize individual or cluster miRNAs identified in this study.

In this study, we validated that overexpression of miR-655-3p and miR-497-5p suppressed the expression of multiple genes (*BCL2*, *CYPLA1*, *DMD*, *FZD6*, *HOXB3*, *MID1*, *NTN*, and *SATB2* by miR-655-3p; and *BAG4*, *CHD7*, *FGFR1*, *FOXP2*, *HECTD1*, *RUNX2*, and *TFAP2A* by miR-497-5p) that are associated with CL/P. Previous studies indicate that miR-655-3p is downregulated in several cancers through dysregulation of ADAM10 (a disintegrin and metalloproteinase domain-containing protein 10) and the WNT/β-catenin pathway \[[@CR58], [@CR59]\]. By contrast, it remains unknown how miR-655-3p expression is induced.

Previous studies also show that miR-497-5p is downregulated in several cancers \[[@CR60]--[@CR62]\]. Interestingly, miR-497-5p is upregulated during myofibroblast differentiation of lung resident mesenchymal stem cells and in the lung tissues of a pulmonary fibrosis mouse model \[[@CR63]\]. While it remains unclear what factors and triggers induce miR-655-3p expression, increased miR-655-3p levels may result in accelerated tissue differentiation with less proliferation in various tissues. Several environmental risk factors for CL/P such as smoking, alcohol consumption and toxins \[[@CR64]\] may cause CL/P through the upregulation of these CL/P-associated miRNAs. In addition, when the levels of these microRNAs are increased too much, multiple CL/P genes would be suppressed, as we demonstrated in this study. Our results may partially explain why individuals with CL/P show suppression of multiple CL/P genes without genetic mutations in the coding regions, which contributes to the complexity of the CL/P etiology.

In this study, we found that miR-497-5p suppressed *CHD7* expression at maximum degree of 80% in cultured human lip fibroblasts. Mutations in *CHD7* cause CHARGE syndrome, which is characterized by CL/P (in 20--36% of the cases), abnormal middle and external ear, coloboma, choanal atresia and hypoplastic semi-circular canals, rhombencephalic dysfunction, hypothalamo- hypophyseal dysfunction, mental retardation, and tracheoesophageal fistula, but do not contribute to nonsyndromic CL/P \[[@CR65]\]. miR- 497-5p also suppressed *RUNX2* expression; SNPs in *RUNX2* are known to increase the risk of nonsyndromic CL/P. Although *FOXP2* and *BAG4* mutations are associated with nonsyndromic CL/P \[[@CR66], [@CR67]\], less is known about the role of these genes in CL/P development. Mouse genetic mutant models are useful tools to investigate the role of genes in lip formation, but the loss of these CL/P genes fails to cause CL/P in mice, although it has not been examined whether suppression of multiple CL/P-associated genes causes CL/P. However, mice deficient for *Tfap2a*, which is suppressed by miR-497-5p, exhibit midfacial cleft \[[@CR68]\], suggesting that *TFAP2A* may be a principal downstream target of miR-497-5p in human lip fibroblasts. Mutations in *TFAP2A* cause Branchio-Oculo-Facial Syndrome (BOFS), which is characterized by CL/P, branchial arch defects, and ocular anomalies \[[@CR69]\], and are associated with nonsyndromic CL/P in several populations. In addition, *Tfap2a* deficiency suppresses *Fgf8* expression in craniofacial regions in mice \[[@CR68]\], suggesting that FGF signaling is a downstream pathway of TFAP2A. In this study, we found that miR-497-5p suppressed *FGFR1* gene expression in cultured human lip fibroblasts. Therefore, a combined downregulation of *TFAP2A* and *FGFR1* may compromise this cascade. *FGFR1* mutations are also associated with increased risk of nonsyndromic CL/P, as well as of Kallmann syndrome with CL/P \[[@CR70]\] and Hartsfield syndrome, which is characterized by holoprosencephaly, ectrodactyly, and CL/P \[[@CR71]\].

miR-655-3p also suppressed the expression of *FZD6*, a WNT receptor, with a maximum reduction of 85%, and of *SATB2* in cultured human lip fibroblasts. Mutations in *FZD6* are found in nonsyndromic CL/P individuals, and SNPs in *SATB2* are associated with nonsyndromic CL/P in several populations. Importantly, mice deficient for *Satb2* also show CL and CP, as seen in individuals with mutations in *SATB2*. Interestingly, wild-type mouse embryos maternally exposed to phenytoin, a drug used to prevent and control seizures but presenting congenital anomalies as common side effects, show decreased *Satb2* expression in craniofacial tissues \[[@CR72]\]. This suggests that miR-655-3p may be upregulated in this condition of CL/P. miR-655-3p also suppressed expression of *DMD* and *MID1* in cultured human fibroblasts. These genes are located on the X chromosome so that their mutations are associated with X-linked nonsyndromic CL/P in men and women. Mutations in *MID1* are associated with the X-linked Opitz G/BBB syndrome, characterized by midline defects such as CL and CP, hypertelorism, and laryngo-trachea-esophageal (LTE) abnormalities \[[@CR73], [@CR74]\]. CYP1A1 is involved in drug/agent metabolism and several of these metabolites are known to be carcinogens \[[@CR75]\]; *CYP1A1* mutations may be associated with CL/P induced with smoking and detoxification \[[@CR76]\]. The role of other downstream targets (*NTN1* and *BCL2*) of miR-655-3p in the CL/P etiology remains largely unknown, and mice deficient for either *Ntn1* or *Bcl2* fail to display CL/P and CP.

Our systematic data collection timely summarizes the CL/P-candidate genes; however, it has some limitations. For example, some genes are from syndromes that include CL/P as a feature, but often they do not. These causative genes may be more broadly related to development, but do not contribute to CL/P; CL/P may be secondary to other defects in these syndromes. The current genetic signature of CL/P or other complex genetic diseases may be due to the bias of the type of genes that have been studied. Unbiased genome sequencing approaches will likely overcome the limitations and help us discover genes associated with CL/P. Molecular profiling of CL/P at the genomic, transcriptomic, regulatory (e.g. enhancer), epigenomic, and proteomic levels in model organisms like mice will provide us with a more detailed and accurate view of how genetic changes cause CL/P.

Conclusion {#Sec22}
==========

Our bioinformatics analysis results suggest that a disruption of extracellular cues and their signaling pathways might be a major cause of CL/P, and that miRNAs might play important roles in the CL/P etiology through the regulation of CL/P genes. In this study, we found that several miRNAs suppressed cell proliferation in cultured human lip fibroblasts. Among them, we confirmed that miR-655-3p and miR497-5p negatively regulated CL/P-candidate genes in the cultured cells. This study will have potential relevance to the miRNA-gene pathways and networks, not only in CL/P but also in other organogenesis processes. Therefore, this study will contribute to a better understanding of the mechanisms of CL/P and to future clinical interventions to prevent and diagnose CL/P.

Additional files
================

 {#Sec23}

Additional file 1:**Table S1.** PCR primer sets used in this study. **Table S2.** Summary of databases searched. **Table S3.** Genes with significant contribution to human CL/P (identified through single gene studies). **Table S4.** Genes with significant contribution to human CL/P (identified through multiple genes studies). **Table S5.** Genes with significant contribution to human CL/P (unknown coding genes). **Table S6.** Genes without significant contribution to human CL/P. **Table S7.** CL/P candidate genes with significant signals in GWAS. **Table S8.** CL/P candidate genes without significant signals in GWAS. **Table S9.** GO terms enriched with genes associated with cleft lip with/without cleft palate (CL/P) in humans. **Table S10.** GO Biological Process terms enriched with human CL/P genes (FDR \< 0.005). **Table S11.** GO Molecular Function terms enriched with human CL/P genes (FDR \< 0.005). **Table S12.** GO Cellular Component terms enriched with human CL/P genes (FDR \< 0.05). **Table S13.** Top 30 Human Phenotype Ontology Categories. **Table S14.** KEGG pathways enriched with genes associated with cleft lip with/without cleft palate (CL/P) in humans. (ZIP 292 kb)

CCDG

:   Center for Craniofacial and Dental Genetics

CL/P

:   Cleft lip with or without cleft palate

DAVID

:   Database for Annotation, Visualization and Integrated Discovery

ECM

:   Extracellular matrix

FDR

:   False Discovery Rate

GO

:   Gene Ontology

GWAS

:   Genome-wide association study

KEGG

:   Kyoto Encyclopedia of Genes and Genomes database

MAPK

:   Mitogen-activated protein kinase

MeSH

:   Medical Subject Headings

MF

:   Molecular function

miRNA

:   microRNA

PI3K

:   Phosphoinositide 3-kinase

SNP

:   Single nucleotide polymorphism

TDT

:   Transmission Disequilibrium Test
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